Nehme El-Hachem

Dr. Nehme El-Hachem


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2013 in Nature
Verified
Journal Article
Closed access
PDF file
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
NENehme El-Hachem
Nehme El-Hachem
ABAnd Nicolai J. Birkbak
And Nicolai J. Birkbak
AJAndrew C. Jin
Andrew C. Jin
ABAndrew H. Beck
Andrew H. Beck
JQJohn Quackenbush
John Quackenbush

21 July 2017 in eLife
Verified
Journal Article
Open access
PGPatrick Grossmann
Patrick Grossmann
OSOlya Stringfield
Olya Stringfield
NENehme El-Hachem
Nehme El-Hachem
MBMarilyn M Bui
Marilyn M Bui
EVEmmanuel Rios Velazquez
Emmanuel Rios Velazquez
HAHugo Jwl Aerts
Hugo Jwl Aerts
Medical imaging can visualize characteristics of human cancer noninvasively. Radiomics is an emerging field that translates these medical images into quantitative data to enable phenotypic profiling of tumors. While radiomics has been associated with several clinical endpoints, the complex relationships of radiomics, clinical factors, and tumor biology are largely unknown. To this end, we analyzed two independent cohorts of respectively 262 North American and 89 European patients with lung cancer, and consistently identified previously undescribed associations between radiomic imaging features, molecular pathways, and clinical factors. In particular, we found a relationship between imaging features, immune response, inflammation, and survival, which was further validated by immunohistochemical staining. Moreover, a number of imaging features showed predictive value for specific pathways; for example, intra-tumor heterogeneity features predicted activity of RNA polymerase transcription (AUC = 0.62, p=0.03) and intensity dispersion was predictive of the autodegration pathway of a ubiquitin ligase (AUC = 0.69, p<10-4). Finally, we observed that prognostic biomarkers performed highest when combining radiomic, genetic, and clinical information (CI = 0.73, p<10-9) indicating complementary value of these data. In conclusion, we demonstrate that radiomic approaches permit noninvasive assessment of both molecular and clinical characteristics of tumors, and therefore have the potential to advance clinical decision-making by systematically analyzing standard-of-care medical images.

3 July 2013 in Bioinformatics
Verified
Journal Article
Open access
PDF file
NJNicolas De Jay
Nicolas De Jay
SPSimon Papillon-Cavanagh
Simon Papillon-Cavanagh
COCatharina Olsen
Catharina Olsen
NENehme El-Hachem
Nehme El-Hachem
Gianluca BontempiGianluca Bontempi
Gianluca Bontempi
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
Motivation: Feature selection is one of the main challenges in analyzing high-throughput genomic data. Minimum redundancy maximum relevance (mRMR) is a particularly fast feature selection method for finding a set of both relevant and complementary features. Here we describe the mRMRe R package, in which the mRMR technique is extended by using an ensemble approach to better explore the feature space and build more robust predictors. To deal with the computational complexity of the ensemble approach, the main functions of the package are implemented and parallelized in C using the openMP Application Programming Interface. Results: Our ensemble mRMR implementations outperform the classical mRMR approach in terms of prediction accuracy. They identify genes more relevant to the biological context and may lead to richer biological interpretations. The parallelized functions included in the package show significant gains in terms of run-time speed when compared with previously released packages. Availability: The R package mRMRe is available on Comprehensive R Archive Network and is provided open source under the Artistic-2.0 License. The code used to generate all the results reported in this application note is available from Supplementary File 1. Contact:bhaibeka@ircm.qc.ca Supplementary information: Supplementary data are available at Bioinformatics online.

9 December 2015 in Bioinformatics
Verified
Journal Article
Open access
PDF file
PSPetr Smirnov
Petr Smirnov
ZSZhaleh Safikhani
Zhaleh Safikhani
NENehme El-Hachem
Nehme El-Hachem
DWDong Wang
Dong Wang
ASAdrian She
Adrian She
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
Summary: Pharmacogenomics holds great promise for the development of biomarkers of drug response and the design of new therapeutic options, which are key challenges in precision medicine. However, such data are scattered and lack standards for efficient access and analysis, consequently preventing the realization of the full potential of pharmacogenomics. To address these issues, we implemented PharmacoGx, an easy-to-use, open source package for integrative analysis of multiple pharmacogenomic datasets. We demonstrate the utility of our package in comparing large drug sensitivity datasets, such as the Genomics of Drug Sensitivity in Cancer and the Cancer Cell Line Encyclopedia. Moreover, we show how to use our package to easily perform Connectivity Map analysis. With increasing availability of drug-related data, our package will open new avenues of research for meta-analysis of pharmacogenomic data. Availability and implementation: PharmacoGx is implemented in R and can be easily installed on any system. The package is available from CRAN and its source code is available from GitHub. Contact: bhaibeka@uhnresearch.ca or benjamin.haibe.kains@utoronto.ca Supplementary information: Supplementary data are available at Bioinformatics online.


9 October 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PSPetr Smirnov
Petr Smirnov
VKVictor Kofia
Victor Kofia
AMAlexander Maru
Alexander Maru
MFMark Freeman
Mark Freeman
CHChantal Ho
Chantal Ho
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
Recent cancer pharmacogenomic studies profiled large panels of cell lines against hundreds of approved drugs and experimental chemical compounds. The overarching goal of these screens is to measure sensitivity of cell lines to chemical perturbations, correlate these measures to genomic features, and thereby develop novel predictors of drug response. However, leveraging these valuable data is challenging due to the lack of standards for annotating cell lines and chemical compounds, and quantifying drug response. Moreover, it has been recently shown that the complexity and complementarity of the experimental protocols used in the field result in high levels of technical and biological variation in the in vitro pharmacological profiles. There is therefore a need for new tools to facilitate rigorous comparison and integrative analysis of large-scale drug screening datasets. To address this issue, we have developed PharmacoDB ( pharmacodb.pmgenomics.ca ), a database integrating the largest cancer pharmacogenomic studies published to date. Here, we describe how the curation of cell line and chemical compound identifiers maximizes the overlap between datasets and how users can leverage such data to compare and extract robust drug phenotypes. PharmacoDB provides a unique resource to mine a compendium of curated cancer pharmacogenomic datasets that are otherwise disparate and difficult to integrate.